Rectify Pharmaceuticals is a biotechnology company developing Positive Functional Modulators (PFMs), disease-modifying therapeutics.
Rectify Pharmaceuticals has raised $100.0M in total funding. The most recent round was Series A. The last funding was announced in October 2021.
Rectify Pharmaceuticals's investors include Omega Funds, Longwood Fund, Atlas Venture, Forbion Capital Partners.
Rectify Pharmaceuticals is headquartered in Cambridge, United States.
Rectify Pharmaceuticals is a biotechnology company developing Positive Functional Modulators (PFMs), disease-modifying therapeutics.
Rectify Pharmaceuticals is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Rectify Pharmaceuticals — Funding & Investors." VCBacked, October 14, 2021, https://www.vcbacked.co/company/rectify-pharmaceuticals. Accessed November 14, 2026.
VCBacked. (2021). Rectify Pharmaceuticals — Funding & Investors. Retrieved November 14, 2026, from https://www.vcbacked.co/company/rectify-pharmaceuticals
{{cite web |title=Rectify Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/rectify-pharmaceuticals |website=VCBacked |access-date=November 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Rectify Pharmaceuticals? Request a listing update